Netherlands-based biotechnology company Azafaros has completed patient recruitmentfor its Phase III study assessing nizubaglustat for GM1/GM2 gangliosidoses
A part of the company’s NAVIGATE programme, the trial aims to assess the effects of nizubaglustat, an orally administered small molecule, on neurological manifestations and disease progression in these rare conditions
Top line results from this trial are expected in early 2028
Advertisement
The NAVIGATE programme consists of two separate randomised, placebo-controlled, multi-centre Phase III trials
The GM1/GM2 gangliosidoses study enrolled at least 75 patients across 25 clinical sites in 13 countries, targeting individuals with late-infantile and juvenile-onset forms of the diseases
Over an 18-month treatment period, patients received either nizubaglustat or placebo. All participants remain eligible to enter an open-label extension period with continued nizubaglustat treatment
Recruitment is still ongoing in a parallel NAVIGATE Phase III study evaluating nizubaglustat in Niemann-Pick type C disease (NPC), where 72 patients are being enrolled
Advertisement
Both trials are taking place at centres in India, Latin America, North America, Pakistan and selected European countries
Azafaros CEO Stefano Portolano said: “Completing enrolment in our Phase III GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases. We are deeply grateful to the patients, caregivers, investigators and advocacy groups who have made this milestone possible
“As we advance the GM1/GM2 study toward data readout and regulatory submission, we continue to enrol in our Phase III NPC study and remain focused on our goal of addressing the significant unmet medical needs faced by these rare disease communities.”
Nizubaglustat is being investigated for its dual mode of action targeting neurological manifestations in lysosomal storage disorders
Advertisement
It has obtained several regulatory designations in the US and Europe, including rare paediatric disease, orphan drug and fast track designations from the US Food and Drug Administration (FDA)
The therapy has also received orphan medicinal product designation from the European Medicines Agency (EMA), and Innovation Passport from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
“Azafaros concludes Phase III trial recruitment for GM1/GM2 gangliosidoses” was originally created and a GlobalData owned brand
